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The use of nanoparticles in treatment and diagnostics of a number of disorders is becoming 
more and more popular. Further investigations are needed for improving the specificity of 
nanoparticle action, precisely targeted drug delivery, decreasing opsonization of nanoparticles 
by macrophages. Numerous ways of nanoparticle surface modification have been successfully 
tested for increasing their therapeutic potential and reducing possible side effects. Nanopar-
ticle encapsulation using plasma membranes of red blood cells as well as other cell types has 
been recently introduced. This field of translational medicine substantially expands opportu-
nities for nanoparticle application in clinical diagnostics and therapy of cancer, cardiovascular 
diseases, in vaccine development etc. This review focuses on ways, advantages and disadvan-
tages of using cellular membranes in nanomedicine. Application of artificial lipid membranes 
in nanoparticles encapsulation is proposed.
Keywords: nanoparticles, cell membranes, liposomes.
Introduction
Drugs administered into human body are nonspecifically distributed in different tis-
sues, which requires injecting big doses of drugs to reach a therapeutic effect resulting 
in undesirable side effects. Thus a targeted drug delivery is vital. One of efficient ways 
for drug’s target delivery is using nanoparticles, the diameter of which is usually below 
100 nm [1; 2]. The properties of nanoparticles are dictated by material they are made from 
as well as their size, form, surface properties, dispersion degree. Extremely small size of 
nanoparticles or rather very high surface area to volume ratio is especially beneficial in 
their use. Nanoparticles for biomedical purposes are currently made from a variety of 
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polymeric materials and minerals, including gelatin, PLGA (poly(lactic-co-glycolic acid)), 
polyacrylamide, lipids, silicon, gold, ferric oxide etc. [3]. Drug-loaded nanoparticles can 
passively accumulate in target tissue, such as tumor, due to the enhanced permeability 
and retention effect [4]. Target delivery can be more precise if nanoparticles have special 
physicochemical properties including their size, surface charge, hydrophilicity and geom-
etry. On the other hand, synthetic nanoparticles can be toxic [2]. What’s more, “naked” 
synthetic nanoparticles can activate the complement system, they are prone to opsoniza-
tion and uptake by macrophages. Administration of nanocarriers also increases the risk 
of anaphylatoxin generation [5]. In order to avoid these side effects, nanoparticles should 
be somehow chemically modified (functionalized) depending on their specific applica-
tion and/or target. The surface of nanoparticles can be modified with ligands, polymers, 
fluorescent labels, enzymes, monoclonal antibodies, aptamers, and other biomolecules. 
Nanoparticle encapsulation into natural cell membranes has recently become one of the 
most popular and universal ways of their functionalization. 
This review focuses on advantages of using cellular membranes in nanomedicine in 
treatment and diagnostics of various diseases. Nanoparticles coated by cell membranes can 
be applied for antimicrobial defense, for creation of more efficient vaccines and so on [6]. 
A method for nanoparticle modification with artificial proteoliposome membranes is 
proposed and its advantages/disadvantages are discussed. 
Nanoparticle encapsulation into cellular membranes 
High density lipoproteins (HDL) can be regarded as natural nanoparticles. They are 
composed of a hydrophobic core that contains triglycerides and cholesterol esters and an 
outer monolayer of phospholipids with some apolipoproteins. These lipoproteins play an 
essential role in cholesterol transport from peripheral tissues to the liver and its removal 
from macrophages in atherosclerotic plaques [7]. Cormode et al made an artificial model 
of HDL, coating nanoparticles with lipids (“HDL”). An APO-I peptide was used instead of 
APO-I apolipoprotein [8]. The core of “HDL” was filled with inorganic nanocrystals made 
of gold and iron oxide serving as contrast agents in molecular visualization. The phospho-
lipid crown of the particles contained lipids carrying fluorescent and paramagnetic labels 
that also served for visualization. These particles can be a valuable tool in multimodal 
diagnostics that combines detection of emission, computer tomography as well as con-
focal and transmission electron microscopy. The artificial “HDL” were stable for at least 
three months, not prone to aggregation and precipitation, exhibited a long lifespan in the 
circulation. They indeed bound to macrophages accumulating in atherosclerotic plaques, 
which is promising for their use in molecular diagnostics.
The “HDL” can be used in studies of HDL-cell interactions, their kinetics and ther-
modynamics. Modulations of these interactions could be achieved by tuning the size of 
the particles. “HDL” are a promising tool for diagnostics of atherosclerosis as well as other 
inflammatory conditions: liver pathologies, rheumatoid arthritis, tumors [8]. 
Liposomes are tiny phospholipid membrane vesicles that represent one of the sim-
plest and most available types of nanoparticles. They can be used for the delivery of drugs 
both hydrophilic (inside liposomes) and hydrophobic (embedded in the lipid bilayer). The 
main disadvantage of liposomes is their low stability. Small (diameter less than 100 nm) 
liposomes are prone to fusion because of high surface curvature and high surface tension. 
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Coating of liposomes with polyethylene glycol stabilizes them, preventing liposome fu-
sion and plasma proteins binding, resulting in longer lifetime of the preparation in the 
circulation [9]. 
A recently proposed encapsulation of nanoparticles into cellular membranes has 
proved a very promising approach. One of the most available sources of cell membrane 
is erythrocytes that are abundant in the blood and easy to operate with. Erythrocyte 
ghosts can be obtained by osmotic shock followed by centrifugation and wash of the 
precipitate in hypotonic buffer. Combination of ultrasound treatment and extrusion 
through polycarbonate filters enables to make membrane vesicles of wanted size. The 
vesicles are then mixed with 70  nm nanoparticles and the preparation is extruded 
through polycarbonate filters once again. As a result, nanoparticles encapsulated into 
erythrocyte membrane are formed. Coating nanoparticles with membranes from other 
cell types is more complicated, but is based on the same principles as in the case of 
erythrocytes [10]. 
Encapsulation into cellular membranes imparts nanoparticles a variety of properties 
that increase opportunities for their use in diagnostics and treatment of various disorders. 
Nanoparticles coated with cell membranes are less prone to aggregation, their colloid sta-
bility is increased [11]. Some advantages of nanoparticle coating technology and its pos-
sible applications in medicine are summarized below.
 — Prolongation of nanoparticles’ circulation lifetime. 
A number of plasma membrane components serve as markers of “self ” cells (autoan-
tigens). CD47  in erythrocyte membranes prevents the uptake of erythrocytes by mac-
rophages (a “don’t eat me” signal) [12; 13]. Other erythrocyte membrane proteins such 
as C8bp (C8 binding protein) [14], decay accelerating factor (DAF), membrane cofactor 
protein (MCP), complement receptor 1 (CR1), CD59 and homologous restriction protein 
(HRP) [15] prevent activation of the complement system [16]. In addition to the proteins, 
phagocytosis of red blood cells (RBCs) is prevented by negatively charged sialic acids in 
the glycocalyx [17]. With help of anti-CD47 antibodies the orientation of the RBC mem-
branes on gold nanoparticles was shown to be the same as in the cells. This is related to 
an asymmetric distribution of the charge of erythrocyte membrane: the outer leaflet of 
the membrane is charged more negatively than the inner one. Hence the negative surface 
charge of gold nanoparticles promotes the correct orientation of the coating erythrocyte 
membrane. 
 — Use of nanoparticles coated with cell membranes for vaccination.
Antibacterial vaccines are routinely made based on inactivated bacterial cells, bacte-
rial proteins or polysaccharides and inactivated bacterial toxins (toxoids). Widespread use 
of these agents led to a substantial reduction of mortality worldwide. With that, effective 
vaccines against Staphylococcus aureus, Helicobacter pylori, Shigella, and Escherichia coli 
have not been created so far. In addition, the application of antibiotics to fight bacterial 
infections results in bacterial antibiotic resistance. A promising alternative for making 
vaccines is encapsulation of nanoparticles in bacterial plasma membranes. 
To this end, two alternatives can be applied: 1) vaccination against virulence factors 
that sequesters bacterial toxins; 2) vaccination against pathogens presenting bacterial an-
tigens [18]. Intact toxins embedded in bacterial membranes (“nanotoxoids”) cannot exert 
their pathogenic effect, but can serve for generation of an immune response. Inactivated 
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(denatured chemically or thermally) toxins are typically used for vaccine production. De-
naturation destroys the three-dimensional structure of a toxin, which changes its anti-
genic determinants and makes it less immunogenic. 
The toxic effect of alpha-hemolysin from Staphylococcus aureus is related to its in-
corporation into RBC membranes and subsequent cell lysis [19]. A vaccine against alpha-
hemolysin (nanotoxoid) was created based on PLGA (poly(lactic-co-glycolic) acid) na-
noparticles coated with RBC membrane. Hemolysin reconstituted into erythrocyte mem-
branes on the surface of nanoparticles retained its antigenic properties and was nontoxic. 
The mice vaccinated intravenously with the nanotoxoid demonstrated a stronger immune 
response than the control group vaccinated with denatured hemolysin. Cell membrane- 
coated nanoparticles may serve as a decoy for bacterial toxins that interact with compo-
nents of the cell membrane. 
The other approach is to use bacterial plasma membrane — coated nanoparticles as 
vaccines. On one hand these formulations have a complete array of antigenic determi-
nants for the immune response. On the other hand the size and form of nanoparticles 
can be easily controlled, which is essential for an efficient presentation of an antigen to 
immune cells. As a result, the effect of combination of nanoparticles and bacterial mem-
branes is synergic leading to amplification of antibacterial immune response. The outer 
membrane vesicles secreted by Gram- negative bacteria, such as E. coli, were used as the 
source of bacterial membrane [18]. 
An antibacterial effect was also manifested in case of nanoparticles coated with plate-
let membranes (PNP). Nanoparticles loaded with the antibiotic vancomycin were more 
efficient against staphylococcus than the antibiotic in solution. This can be explained by 
capability of platelet cell membrane components for specific interactions with staphylo-
cocci and streptococci [5]. 
 — Application of encapsulated nanoparticles for detoxification.
Unfortunately, critical care units pretty often admit patients that got a dangerous 
dose of a highly active poison or drug either incidentally or as a result of suicide at-
tempt. Among the most lethal poisons are organophosphorus compounds including in-
secticides, pesticides and neuroparalytic warfare agents such as sarin and saman. Their 
toxicity is caused by irreversible inhibition of acetylcholinesterase at negligibly small 
concentrations — 10–7 M or less [20]. Organophosphates phosphorylate the catalytic 
serine hydroxyl at the active site of acetylcholinesterase leading to accumulation of ace-
tylcholine in synapses and disruption of cholinergic synaptic transmissions. This can 
result in neurotoxic effects and even death. Development of an effective antidote for 
this type of compound and other toxic agents continues to be relevant. Pang et al. [21] 
used nanoparticles coated with RBC membrane for detoxification of the organophos-
phorus compound dichlorvos. Acetylcholinesterase in erythrocyte membranes on the 
surface of nanoparticles was able to efficiently bind dichlorvos intravenously injected 
in mice, protecting the synaptic acetylcholinesterase thereby preventing or mitigating 
the poisoning. When dichlorvos was injected alone, all the mice used perished within 
an hour. But upon the combined injection of dichlorvos and nanoparticles coated with 
RBC membranes all the mice treated remained alive for at least 16 more days. Thus na-
noparticles encapsulated in cellular membranes can be used as effective antidots coun-
teracting diverse toxins and poisons. 
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 — Application of nanoparticles coated with cell membranes in treatment of autoim-
mune disorders. 
Idiopathic thrombocytopenic purpura is a condition in which autoantibodies attack 
host platelets, resulting in uncontrolled bleeding that can be fatal. In vitro and in vivo 
tests on blood coagulation in mice demonstrated that nanoparticles coated with platelet 
membranes efficiently bind platelet autoantibodies, preventing platelet destruction in the 
reticuloendothelial system in thrombocytopenia [22]. 
 — Targeted delivery of drugs. 
Nanoparticles coated with cell membranes are able to accumulate in target organ 
using homotypic and heterotypic adhesive properties of cell membranes. For example, 
tumor cells express CD44 on their surface [23]. Nanoparticles encapsulated into platelet 
membranes containing P-selectin mainly accumulate in a tumor (heterotypic adhesion). 
On the other hand, diverse tumor cells express surface antigens with homophilic adhe-
sive domains such as carcinoembryonic antigen and galectin-3 necessary for formation 
of multicellular aggregates in tumors. The heterotypic adhesion to the microvascular en-
dothelium and subsequent homotypic aggregation are critical in the generation of metas-
tases in the blood [1]. 
Cell’s capability of heterotypic and homotypic adhesion underlies the use of nanopar-
ticles for precise targeted drug delivery, which, in particular, can be applied in photody-
namic therapy for treating cancer. 
As an example, PLGA nanoparticles (negative surface charge) were coated with plate-
let membranes (NP-P) or RBC membranes (NP-R), the nanoparticles being preliminary 
loaded with the photosensitizer verteporfin [24]. Upon intravenous injection in BALB/c 
mice with tumor 4T1 the nanoparticles were distributed to different organs. Remarkably, 
the accumulation of the NP-P in the tumors substantially exceeded that of the NP-R. The 
subsequent laser irradiation (at 680–730 nm, near the absorption maximum of verteporfin 
in nanoparticles) led to a much more pronounced tumor shrinking in case of the NP-P 
compared compared with the NP-R. The survival rate of the mice for 35 days starting from 
the injection was 100 % in case of NP-P, 75 % in case of NP-R, 0 % in case of phosphate 
buffered saline without NP.
Nanoparticles encapsulated in cancer cell membranes may play a double role. On one 
hand, they can be used for vaccination against cancer as due to the membrane they carry 
tumor antigens, and can also be supplied by immunologic adjuvant. As a result, upon 
interaction with antigen-presenting cells these nanoparticles are able to cause an antitu-
mor immune response. On the other hand, carrying the same adhesion molecules as the 
membranes of tumor cells the nanoparticles are capable of specific binding to these cells 
owing to homotypic interaction [25]. 
One of anticancer vaccines actively used is Provenge (Sipuleucel-T). It can be ap-
plied for treatment of adenoma. For generation of this vaccine prostate acid phosphatase 
is used [26]. 
As noted above, nanoparticles coated with tumor cell membranes can improve the 
efficiency of vaccination against cancer due to various membrane -bound cancer antigens. 
In addition, the nanoparticles can be loaded with adjuvant. 
It is also possible to combine platelet and RBC membrane when coating nanoparti-
cles [27]. The nanoparticles encapsulated in platelet/RBC membranes exhibited proper-
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ties typical for both platelet and erythrocyte membranes. Thus, their applications in the 
clinic can be broader than in the case of nanoparticles coated with membranes from single 
source. 
 — Issues that affect the application of nanoparticles encapsulatedin cell membranes.
This review clearly shows that the technology of encaplsuting nanoparticles in cell 
membranes is very promising for the treatment and diagnostics of a wide range of disor-
ders. With that, there are some drawbacks of this type of nanoparticles:
 — laborious procedures of obtaining cell membranes. RBC membranes are relatively 
easily isolated and available. The isolation of platelet membranes is much more 
complicated and costly, in particular, it requires protease inhibitors, and platelet 
aggregation should be avoided. Most other cell types can be obtained from the 
respective cell lines. 
 — very low yield of nanoparticles coated with cell membranes.
 — cell membranes contain both “useful” proteins that serve for nanoparticle binding 
to therapeutic targets and a big number of other proteins that may generate im-
mune reactions. 
 — the absence of clear criteria for estimation of the quality of biologic material used 
for preparation of cell membrane encapsulated nanoparticles; the safety of these 
preparations is not completely proven [28]. 
Possibilities of coating nanoparticles with modular 
proteoliposome membranes
Artificial lipid membranes can be used to mimic the natural cell membranes. This ap-
proach allows to use any suitable types of lipids for controlled reconstitution of membrane 
proteins, both recombinant and artificially constructed, into liposomes. For reconstitution 
of a membrane protein in liposomes it should be first mixed with a detergent and unila-
mellar liposomes (lipid bilayer) with subsequent removal of the detergent with help of 
gel-filtration, dialysis etc. [29].
The formation of proteoliposomes usually includes the following steps: 
1) extraction of membrane proteins using detergents;
2) purification of the protein of interest;
3) preparation of unilamellar liposomes;
4) solubilization of the liposomes with detergents and formation of lipid-detergent 
micelles with subsequent adding the protein. As a result, mixed protein/lipid/
detergent micelles; 
5) removal of detergents and formation of proteoliposomes.
The method described works well for small liposomes (diameter = 30–200 nm), but 
is not that efficient in case of large (200–1000 nm) and giant (more than 1 micron) li-
posomes. 
Proteoliposomes containing different proteins may fuse due to oppositely charged 
lipids [30–33]. 
Liposomes made mainly of phosphatidylcholine were charged due to 10–40 % either 
negatively or positively charged lipids (anionic or cationic liposomes, respectively). A pro-
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ton gradient generator, E. coli complex IV (bo3 oxidase), was reconstituted in the cationic 
liposomes, while E. coli F0F1-ATPase was reconstituted in the anionic liposomes [30; 31]. 
The two proteoliposome preparations were mixed. Fusion of the proteoliposomes was 
completed in 5–10 min, which could be confirmed by detecting ATP synthesis (Fig. 1). 
The efficiency of proteoliposomes fusion critically depended on the fraction of charged 
lipids, temperature and liposome size. Smaller liposomes fuse faster due to higher surface 
curvatures. A drawback of this method is using cationic lipids that do not occur naturally, 
so it is necessary to test effects of these lipids on the activity of membrane proteins. 
The modular (proteo)liposomes resulting from fusion of oppositely charged (proteo)
liposomes can be exploited for coating nanoparticles (Fig. 2). 
This putative procedure could include the following steps. 
 — First, preparation of proteoliposomes containing at least two types of proteins: 
1) those functioning as a “don’t eat me” signal, like СВ47 from RBC; 2) those spe-
cifically interacting with the target cells. The binary system is possible when the 
proteins are first reconstituted into oppositely charged liposomes that can fuse, 
forming proteoliposomes containing both proteins. In case of the ternary system, 
both types of proteins are initially reconstituted into positively charged liposomes. 
Then the two preparations of proteoliposomes containing one of the proteins fuse 
with negatively charged large or giant liposomes. 
 — Next step: the modular proteoliposomes obtained in step one are mixed with na-
noparticles that are coated with the proteoliposomes membranes by means of ul-
trasound or extrusion through polycarbonate filters. 
Some advantages of the proposed approach are as follows. 
 — Purified (recombinant) proteins can be used. Modern purification procedures 
allow to get big amounts of homogenous highly active protein. In particular, the 
Fig. 1. Fusion of proteoliposomes containing components of the bacterial 
respiratory chain. E. coli F0F1-ATPase and bo3 oxidase were reconstituted into 
anionic and cationic liposomes, respectively. The efficiency of proteoliposomes’ 
fusion was estimated by adding the substrates of both enzymes to the incubation 
medium. Proton gradient generated by bo3 oxidase caused formation of ATP 
detected with the luciferin-luciferase system. See the text for further explanation 
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use of affinity chromatography (for example, Ni-NTA agarose that is capable of 
tight binding of hexahistidine tags in recombinant proteins) facilitates prepara-
tion of a homogenous pure protein. As noted above, the cell membranes contain 
both “necessary” proteins that serve for binding to the target cells and a lot of 
other proteins that can induce immune responses. Proteoliposomes, contrary to 
natural cell membranes, can be enriched in the “necessary” proteins, resulting 
in a more tight and specific interactions of the nanoparticles with their targets. 
In addition, other membrane proteins do not interfere with those interactions. 
What’s more, cell material is often not enough for clinically meaningful nano-
particle encapsulation;
 — Immense opportunities for selection of optimal lipids (and their combinations) 
based on chemical properties, charge and other parameters for exertion of the 
required biomimetic effect.
 — Possibility for standardization of the material created and clear criteria for its 
quality control.
Concerning possible drawbacks of application of artificial membrane vesicles. One 
of them is necessity for purification of homogenous proteins. Protein purification is often 
very difficult, mutistep and expensive process. In the case of recombinant proteins a tissue 
cell culture with strict sterility and safety rules is required. 
Fig. 2. Diagram of putative encapsulation of nanoparticles into fused proteoliposome mem-
branes. a) obtaining proteoliposomes containing a target tissue binding protein; b) fusion of op-
positely charged proteoliposomes containing a target tissue binding protein as well as a “don’t eat 
me signal” protein, with formation of combined proteoliposomes (binary system); c) prepara-
tion of positively charged proteoliposomes containing either a target tissue binding protein or a 
“don’t eat me signal” protein followed by fusion of both types of proteoliposomes with negatively 
charged large or giant liposomes. Encapsulation of nanoparticles can be carried out by treatment 
of the combined proteoliposomes by ultrasound or extrusion using polycarbonate filters. See the 
text for further explanation
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Conclusion
This review describes the ways of nanoparticle encapsulation in the cell membranes 
as well as possibilities of using this technology in modern medicine, both in therapy and 
diagnostics. Coating nanoparticles with cell membranes prolongs their circulation life-
time, increases their colloidal stability. Nanoparticles encapsulated in cell membranes can 
be used as efficient vaccines against infections and tumors. They also promote precise 
targeted delivery of drugs and can be used in treatment of autoimmune disorders. The 
encapsulated nanoparticles have potential for detoxification of natural (produced by mi-
crobe) and chemical toxins. It is evident that the number of applications of these nanopar-
ticles will expand. Using artificial lipid membranes mimicking cell membranes in coating 
nanoparticles is proposed. 
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